Should Low-Dose Aspirin Be Started After AVF Thrombectomy?
Based on the available evidence, aspirin should NOT be routinely started after arteriovenous fistula (AVF) thrombectomy, as high-quality randomized trials show no benefit in preventing fistula failure, and there are significant bleeding risks in this population. 1
Evidence Against Routine Aspirin Use
The 2020 KDOQI Clinical Practice Guideline for Vascular Access explicitly states: "KDOQI does not suggest the routine use of fish oil or aspirin to prevent AVF flow dysfunction." 1 This recommendation is based on moderate-quality evidence and directly addresses the dialysis access population.
The FAVOURED trial (2017), the largest and highest-quality study on this topic, randomized 567 patients with new AVFs to aspirin 100 mg daily versus placebo for 12 weeks. The results showed no reduction in fistula failure (45% vs 43%; RR 1.05,95% CI 0.84-1.31), thrombosis, abandonment, or cannulation failure. 2 This was a well-designed, double-blind RCT that definitively demonstrated aspirin provides no benefit for AVF patency.
Bleeding Risk Considerations
Aspirin poses particular bleeding risks in dialysis patients due to uremic platelet dysfunction. Research demonstrates that even moderate-dose aspirin (100 mg/m²) significantly prolongs bleeding time in uremic patients on hemodialysis, with 12 of 29 patients developing bleeding times >15 minutes. 3 The study concluded that "careful risk-benefit evaluation is necessary before giving aspirin to uremic patients on hemodialysis."
Absolute Contraindications to Aspirin:
- Active bleeding or recent major hemorrhage
- Known aspirin allergy or intolerance
- Severe thrombocytopenia (platelet count <50 × 10⁹/L based on vascular access guidelines) 4
- Concurrent therapeutic anticoagulation without compelling indication
- Pregnancy (especially last 3 months) 5
Relative Contraindications:
- History of gastrointestinal bleeding or peptic ulcer disease
- Age >70 years
- Concurrent use of NSAIDs or other antiplatelet agents
- Coagulopathy or bleeding disorders
- Chronic kidney disease with uremic bleeding tendency 6
When Aspirin Might Be Considered
The only scenario where aspirin showed potential benefit was in observational data from patients presenting with acute AVF failure requiring endovascular salvage. One study found aspirin therapy was associated with longer primary patency (HR 0.6, p=0.02) after thrombectomy procedures. 7 However, this was retrospective observational data, not a randomized trial, and the authors themselves stated "aspirin therapy for patients presenting with failure of fistulae deserves further investigation."
Alternative Approaches
For AVF grafts (not native fistulas), the evidence differs slightly. KDOQI suggests careful consideration of combination dipyridamole (200 mg) and aspirin (25 mg) twice daily to improve AVG primary unassisted patency 1, though this applies to grafts, not native fistulas.
Clinical Algorithm
After AVF thrombectomy:
Do NOT routinely start aspirin - no proven benefit for native AVF patency 1, 2
Assess bleeding risk factors:
- Check platelet count, PT/INR, aPTT
- Review medication list for anticoagulants/antiplatelets
- Evaluate for uremic bleeding tendency
Focus on addressing the underlying stenosis:
- Ensure adequate treatment of culprit lesion with angioplasty 1
- Consider surveillance for recurrent stenosis
- Optimize dialysis adequacy
Consider aspirin ONLY if:
Common Pitfalls
- Assuming aspirin helps AVF patency because it helps coronary/peripheral arterial disease - the pathophysiology differs, and RCT evidence shows no benefit
- Continuing aspirin "just in case" - exposes patients to bleeding risk without proven benefit
- Not checking for uremic platelet dysfunction - dialysis patients have baseline platelet abnormalities that aspirin worsens
- Using higher aspirin doses - if aspirin is indicated for cardiovascular reasons, use 75-81 mg daily, not 325 mg 8, 9